Africa produces about 2.0% of world research output, yet the region, as defined by UNESCO, accounts for 15.0% of the global population and 25.0% of the global disease burden. Research and development (R&D) pipelines for diseases that disproportionately affect African countries and address Africa’s unmet health needs are insufficient. The African region comprises 15.0% of the world’s population, yet only accounted for 1.1% of global investments in R&D in 2016. There were substantial disparities within the continent, with Egypt, Nigeria and South Africa contributing 65.7% of the total R&D spending. In most countries of the Organization for Economic Co-operation and Development, the largest source of R&D funding is the private sector. R&D in Africa is mainly funded by the public sector, with significant proportions of financing in many countries coming from international funding. Challenges that limit private sector investment include unstable political environments, poor governance, and corruption.
Evidence suggests various research output and research capacity limitations in Africa when considering a global context. Metrics that reflect this include university rankings, number of researchers, number of publications, clinical trials networks and pharmaceutical manufacturing capacity. Within the continent there are substantial regional disparities. Incentivizing investment is crucial to foster current and future research output and research capacity.
In this perspective, it is important to develop and implement coordination platforms where African actors involved in Global Health Research and Development and more broadly in public health will have the opportunity to reflect together on the challenges facing Africa.
Creating a regional working group regrouping like-minded partners from NGOs, CSOs, academic institutions, research institutions and private sector to advance policies to accelerate the creation of new drugs, vaccines, diagnostics, medical devices and other tools that bring healthy lives within reach for all people. Our focus will be to spark collaboration around the need for advocacy for increased investment and advancing policies to accelerate the R&D of new health technologies that address critical health challenges, such as HIV/AIDs, malaria, tuberculosis, maternal and child health, and other neglected diseases.
The mission of the Regional Working Group is to support actions to achieve disease elimination goals through increased funding for research and development.
The Regional Advocacy Working Group aims to celebrate successes, influence policies and practices, consolidate knowledge, use, and showcase innovative approaches for health innovation in Africa.
Goal and Objectives
The Regional Advocacy Working Group is intended to be a platform that any NGOs, CSOs, academia, research institutions and aligned private sector companies working in advocacy and public health can join. It aims to provide an exchange and communication framework for actors to share knowledge and information on ways to best engage in R&D across the continent. More specifically the Working Group aims to:
Modalities of cooperation
Benefits for Members
List of Potential Participants
How to Apply
Interested in this opportunity ?